In a paper by Shen et al. [51], the authors checked whether knockdown of ANGPTL4 and NADPH oxidase 4 (NOX4) would provide new targets to improve the outcomes in patients with hyperlipidemia-associated CRC metastasis. This evidence concerns the gene NOX4 and hyperlipidemia.